TY - JOUR
T1 - Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer
AU - Song, Mihae
AU - Dipaola, Robert S.
AU - Cracchiolo, Bernadette M.
AU - Gibbon, Darlene G.
AU - Hellmann, Mira
AU - Nieves-Neira, Wilberto
AU - Vaidya, Ami
AU - Wagreich, Allison R.
AU - Shih, Weichung J.
AU - Rodriguez-Rodriguez, Lorna
N1 - Publisher Copyright:
Copyright © 2014 by IGCS and ESGO.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Objective: Overexpression of bcl-2 is a mechanism of drug resistance in cervical cancer. Agents that down-regulate bcl-2 may decrease tumor cell threshold and sensitize tumor cells to chemotherapy. The objective of this multi-institutional phase 2 trial was to evaluate the efficacy and toxicity of paclitaxel and bcl-2 modulators (13-cis retinoic acid and interferon alfa-2b) in patients with advanced-stage or recurrent cervical cancer. Materials and Methods: Patients had biopsy-proven metastatic, first relapse, or persistent cervical cancer with no prior chemotherapy except for chemosensitizing agents. The treatment consisted of oral 13-cis retinoic acid, 1 mg/kg, and subcutaneous interferon alfa-2b, 6 mU/m2, days 1 to 4, and intravenous paclitaxel, 175 mg/m2, day 4 until disease progression or adverse events prohibited treatment. The primary endpoint was overall response rate. Results: Thirty-three patients were enrolled between March 2001 and June 2009. Thirtyone patients were eligible for evaluation of treatment response. Twenty-seven patients (82%) received prior concurrent chemoradiation or radiotherapy alone before study enrollment. The overall response rate was 30% (6 complete responses and 4 partial responses). Furthermore, 7 patients (21%) had stable disease. Grade 3 or 4 adverse events included neutropenia (n =16 [48%]), febrile neutropenia (n = 1 [3%]), and anemia (n = 1 [3%]). There were no treatment-related deaths. The median progression-free survival was 3.4 months (95% confidence interval, 2.0Y7.4 months), and overall survival was 11.2 months (95% confidence interval, 7.5Y26.2 months). Of 6 patients with complete responses, 5 patients survived more than 2 years. Conclusions: Combination therapy with paclitaxel, 13-cis retinoic acid, and interferon alfa-2b is feasible and safe in treating patients with advanced and recurrent cervical cancer.
AB - Objective: Overexpression of bcl-2 is a mechanism of drug resistance in cervical cancer. Agents that down-regulate bcl-2 may decrease tumor cell threshold and sensitize tumor cells to chemotherapy. The objective of this multi-institutional phase 2 trial was to evaluate the efficacy and toxicity of paclitaxel and bcl-2 modulators (13-cis retinoic acid and interferon alfa-2b) in patients with advanced-stage or recurrent cervical cancer. Materials and Methods: Patients had biopsy-proven metastatic, first relapse, or persistent cervical cancer with no prior chemotherapy except for chemosensitizing agents. The treatment consisted of oral 13-cis retinoic acid, 1 mg/kg, and subcutaneous interferon alfa-2b, 6 mU/m2, days 1 to 4, and intravenous paclitaxel, 175 mg/m2, day 4 until disease progression or adverse events prohibited treatment. The primary endpoint was overall response rate. Results: Thirty-three patients were enrolled between March 2001 and June 2009. Thirtyone patients were eligible for evaluation of treatment response. Twenty-seven patients (82%) received prior concurrent chemoradiation or radiotherapy alone before study enrollment. The overall response rate was 30% (6 complete responses and 4 partial responses). Furthermore, 7 patients (21%) had stable disease. Grade 3 or 4 adverse events included neutropenia (n =16 [48%]), febrile neutropenia (n = 1 [3%]), and anemia (n = 1 [3%]). There were no treatment-related deaths. The median progression-free survival was 3.4 months (95% confidence interval, 2.0Y7.4 months), and overall survival was 11.2 months (95% confidence interval, 7.5Y26.2 months). Of 6 patients with complete responses, 5 patients survived more than 2 years. Conclusions: Combination therapy with paclitaxel, 13-cis retinoic acid, and interferon alfa-2b is feasible and safe in treating patients with advanced and recurrent cervical cancer.
KW - 13-cis retinoic acid
KW - Cervical cancer
KW - Interferon alfa-2b
KW - Paclitaxel
UR - http://www.scopus.com/inward/record.url?scp=84925954261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925954261&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000258
DO - 10.1097/IGC.0000000000000258
M3 - Article
C2 - 25304678
AN - SCOPUS:84925954261
SN - 1048-891X
VL - 24
SP - 1636
EP - 1641
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 9
ER -